EGFR and lung carcinoma: Mounting studies have indicated that YAP overexpression enhances resistance to EGFR-TKIs (like the first-generation inhibitors gefitinib and erlotinib, second-generation inhibitor afatinib, and third-generation inhibitor osimertinib) in multiple lung cancer cell lines; whereas YAP knockdown restores EGFR-TKI sensitivity [68,69,70,71] (Table 1).